EZ-editor™ technology (CRISPR based), developed by Ubigene, is more efficient than general
CRISPR/Cas9 technology in double-strand breaking and homologous recombination. With EZ-editor™, Ubigene has
successfully edited over 8000 genes on more than 300 types of cell lines.
Objective
To create a Human PNPT1 Knockout
model in cell line by EZ-editor™-mediated genome engineering.
Target gene info
Official symbol
PNPT1
Gene id
87178
Organism
Homo sapiens
Gene type
protein-coding
Official full symbol
polyribonucleotide nucleotidyltransferase 1
Also known as
COXPD13, DFNB70, OLD35, PNPASE, old-35
Genomic regions
Chromosome 2
Summary
The protein encoded by this gene belongs to the evolutionary conserved polynucleotide phosphorylase family comprised of phosphate dependent 3'-to-5' exoribonucleases implicated in RNA processing and degradation. This enzyme is predominantly localized in the mitochondrial intermembrane space and is involved in import of RNA to mitochondria. Mutations in this gene have been associated with combined oxidative phosphorylation deficiency-13 and autosomal recessive nonsyndromic deafness-70. Related pseudogenes are found on chromosomes 3 and 7.
Strategy Summary
This gene has 0 protein coding transcripts：
Frame-shift
Fragment A
Fragment B
gRNA Detail
Strategy
Project Comprehensive Difficulty Assessment
According to the Red Cotton database: the PNPT1 gene is evaluated as high lethality riskin cell line, and the CRISPR gene-editing strategy design is Unknown. Knockout project comprehensive difficulty is thus assessed as Unknown. KO experiment is not recommended.
In all cell lines, there is
4.0% cells with low expression level,
96.0% cells with medium expression level
of PNPT1 gene.
Cell line is not selected, unable to assess the accurate expression level, for reference only.
In all cell lines, there is
55.2% cells with low copy number,
40.6% cells with medium copy number,
4.2% cells with high copy number
of PNPT1 gene.
Cell line is not selected, unable to assess the accurate copy number, for reference only.
Ubigene is an international high-technology enterprise focused on gene-editing cells. Our exclusive EZ-editor™ technology has 10-20 times more efficient editing than traditional methods, easily achieving gene knockout, point mutation, and knock-in. Based on EZ-editor™ technology, Ubigene has accumulated over 6000 successful gene-editing cases from more than 300 cell lines including iPSC and ESC, and has established a KO Cell Line Bank with 5000+ KO cell lines and Red Cotton™ gRNA Plasmid Bank with 10000+ gRNA plasmids available in stock.
Ubigene focuses on technological innovation and product development, of which EZ-editor™ series products that cover the whole workflow of gene-editing keep improving. Ubigene will move on toward our goal of "Make genome editing easier" and we won't stop!
EZ-editor™ Gene Dependency
EZ-editor™ Gene Expression Level 
EZ-editor™ Gene Copy Number 
